Drug Profile
Research programme: acetyl-CoA carboxylase inhibitors - Pfizer
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pfizer
- Class
- Mechanism of Action Acetyl-CoA carboxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
- Discontinued Obesity
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA
- 26 Aug 2010 Preclinical trials in Type-2 diabetes mellitus in USA (unspecified route)
- 13 Sep 2004 Preclinical trials in Obesity in USA (unspecified route)